Published in Infect Immun on March 01, 1980
Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J Clin Microbiol (1986) 2.67
Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines. Infect Immun (1982) 2.61
Effectiveness of reverse transcription-PCR, virus isolation, and enzyme-linked immunosorbent assay for diagnosis of influenza A virus infection in different age groups. J Clin Microbiol (2002) 2.13
Dose response of A/Alaska/6/77 (H3N2) cold-adapted reassortant vaccine virus in adult volunteers: role of local antibody in resistance to infection with vaccine virus. Infect Immun (1983) 2.01
Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats. J Virol (2007) 1.24
Attenuation of wild-type human influenza A virus by acquisition of the PA polymerase and matrix protein genes of influenza A/Ann Arbor/6/60 cold-adapted donor virus. J Clin Microbiol (1985) 1.22
An alphavirus replicon-based human metapneumovirus vaccine is immunogenic and protective in mice and cotton rats. J Virol (2008) 0.98
New aspects of influenza viruses. Clin Microbiol Rev (1992) 0.97
Serological evaluation of an influenza A virus cold-adapted reassortant live vaccine, CR-37 (H1N1), in Japanese adult volunteers. J Hyg (Lond) (1984) 0.82
Serum neutralizing antibody and lymphocyte transformation responses after influenza B virus infections. J Clin Microbiol (1983) 0.75
Effect of virus infections on the function of the immune system. Annu Rev Microbiol (1970) 4.30
Adaptation and growth characteristics of influenza virus at 25 degrees c. Nature (1967) 3.41
Biologic and immunologic characteristics of cold-adapted influenza virus. J Immunol (1969) 3.17
Lymphocyte interferon production and transformation after Herpes simplex infections in humans. J Immunol (1974) 2.64
Interferon production in children with respiratory syncytial, influenza, and parainfluenza virus infections. J Pediatr (1978) 2.01
Participation of lymphocytes in viral infections. Adv Immunol (1973) 2.01
A comparative study of attenuated influenza viruses. Bull World Health Organ (1971) 1.81
Decreased skin-test reactivity associated with influenza. J Infect Dis (1972) 1.74
Temperature-sensitive mutants of influenza virus. IV. Induction of interferon in the nasopharynx by wild-type and a temperature-sensitive recombinant virus. J Infect Dis (1973) 1.70
Interferon in nasal secretions from infants with viral respiratory tract infections. J Pediatr (1978) 1.61
Safety and antigenicity of temperature sensitive (TS) mutant respiratory syncytial virus (RSV) in infants and children. Pediatrics (1973) 1.57
Humoral and cellular response in humans after immunization with influenza vaccine. Infect Immun (1973) 1.54
Safety and antigenicity of influenza A/Hong Kong/68-ts-1 (E) (H3N2). J Pediatr (1975) 1.45
Immunosuppression during influenza virus infection. Infect Immun (1974) 1.45
Production of interferon in volunteers infected with Asian influenza. J Infect Dis (1970) 1.33
Effect of viral and bacterial pneumonias on cell-mediated immunity in humans. Infect Immun (1976) 1.29
Pilot studies on recombinant cold-adapted live type A and B influenza virus vaccines. J Infect Dis (1977) 1.25
Cell-mediated immune responses in humans after induced infection with influenza A virus. J Infect Dis (1977) 1.20
Cell-mediated immune responses to the hemagglutinin and neuraminidase antigens of influenza A virus after immunization in humans. Infect Immun (1979) 1.03
Low-Temperature-Adapted Influenza A2/AA/6/60 Virus Vaccine in Man. Infect Immun (1973) 1.03
Lymphocyte blastogenic responses to influenza virus antigens after influenza infection and vaccination in humans. Infect Immun (1978) 1.01
Cell-mediated immunity in humans during viral infection: dermal hypersensitivity and in vitro lymphocyte proliferation during mild viral respiratory infections. Infect Immun (1974) 0.91
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med (2005) 17.06
The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med (2000) 8.46
Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr (2000) 4.08
Primary respiratory syncytial virus infection in mice. J Med Virol (1988) 3.77
Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest (1991) 3.71
Experimental respiratory syncytial virus infection of adults. Possible mechanisms of resistance to infection and illness. J Immunol (1971) 3.33
Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis (1992) 3.07
Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines. Infect Immun (1982) 2.61
A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis (1994) 2.52
Enterovirus 71 from fatal and nonfatal cases of hand, foot and mouth disease epidemics in Malaysia, Japan and Taiwan in 1997-1998. Jpn J Infect Dis (1999) 2.52
Canine kidney cell line for isolation of respiratory viruses. J Clin Microbiol (1979) 2.25
Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children < 5 years old. J Infect Dis (1997) 2.12
Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection. J Clin Microbiol (1986) 2.09
Comparison of competitive and indirect enzyme-linked immunosorbent assays for detection of bluetongue virus antibodies in serum and whole blood. J Clin Microbiol (1987) 2.07
Surveillance of viral gastroenteritis in Japan: pediatric cases and outbreak incidents. J Infect Dis (2000) 2.04
Differing virulence of H1N1 and H3N2 influenza strains. Am J Epidemiol (1980) 1.97
Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. J Infect Dis (1986) 1.97
Temperature-sensitive mutants of respiratory syncytial virus. J Virol (1969) 1.94
Epidemiology of influenza A(H1N1)v virus infection in Japan, May-June 2009. Euro Surveill (2009) 1.91
Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr Infect Dis J (2001) 1.90
Comparison of long-term systemic and secretory antibody responses in children given live, attenuated, or inactivated influenza A vaccine. J Med Virol (1985) 1.88
Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J Infect Dis (1997) 1.86
The burden of influenza illness in children with asthma and other chronic medical conditions. J Pediatr (2000) 1.85
Evaluation of disease activity in patients with moderately active ulcerative colitis: comparisons between a new activity index and Truelove and Witts' classification. Am J Gastroenterol (1995) 1.85
Sustained transmission of mumps in a highly vaccinated population: assessment of primary vaccine failure and waning vaccine-induced immunity. J Infect Dis (1994) 1.78
Adenovirus infections in young children. Pediatrics (1985) 1.76
Changing presentation of herpes simplex virus infection in neonates. J Infect Dis (1988) 1.76
Genetic analyses of GII.17 norovirus strains in diarrheal disease outbreaks from December 2014 to March 2015 in Japan reveal a novel polymerase sequence and amino acid substitutions in the capsid region. Euro Surveill (2015) 1.73
A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children. J Infect Dis (1995) 1.68
Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. J Infect Dis (1993) 1.67
Cytomegalovirus pneumonia in two infants recently adopted from China. Clin Infect Dis (1999) 1.65
The natural history of human immunodeficiency virus 1 infection in Haitian infants. Pediatr Infect Dis J (1999) 1.64
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis (1998) 1.64
Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children. Infect Immun (1982) 1.61
Cold-adapted recombinant influenza A virus vaccines in seronegative young children. J Infect Dis (1982) 1.61
Development of subtype-specific and heterosubtypic antibodies to the influenza A virus hemagglutinin after primary infection in children. J Clin Microbiol (1985) 1.59
Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis. Aliment Pharmacol Ther (2014) 1.56
Experience with percutaneous dilational tracheostomy. Ann Otol Rhinol Laryngol (2000) 1.56
Interpersonal influences in adolescent drug use--the role of older siblings, parents, and peers. Int J Addict (1986) 1.53
Strain-specific serum antibody responses in infants undergoing primary infection with respiratory syncytial virus. J Infect Dis (1988) 1.52
Twenty years of outpatient respiratory syncytial virus infection: a framework for vaccine efficacy trials. Pediatrics (1997) 1.51
Temperature-sensitive mutants of respiratory syncytial virus: in-vivo studies in hamsters. J Infect Dis (1970) 1.51
Prevention of transfusion-associated cytomegalovirus infection in neonatal patients by the removal of white cells from blood. Transfusion (1992) 1.47
Comparison of influenza B/Hong Kong virus infections among infants, children, and young adults. J Infect Dis (1980) 1.47
Structures of recombinant native and E202Q mutant human acetylcholinesterase complexed with the snake-venom toxin fasciculin-II. Acta Crystallogr D Biol Crystallogr (2000) 1.47
Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group. J Infect Dis (1998) 1.47
Safety and antigenicity of influenza A/Hong Kong/68-ts-1 (E) (H3N2). J Pediatr (1975) 1.45
Candidate AIDS vaccines. N Engl J Med (1995) 1.41
Antibody-dependent cell-mediated cytotoxicity against influenza virus-infected cells. J Infect Dis (1983) 1.41
Management of myasthenia gravis. J Assoc Physicians India (1991) 1.39
A comparative study of once-a-day morning and once-a-day bedtime administration of 40 mg famotidine in treating gastric ulcers. Am J Gastroenterol (1992) 1.39
Reinfection of mice with respiratory syncytial virus. J Med Virol (1991) 1.39
Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children. Vaccine (1999) 1.37
Genetic studies of respiratory syncytial virus temperature-sensitive mutants. Arch Gesamte Virusforsch (1973) 1.36
A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children. J Infect Dis (1995) 1.36
Influenza A infections in young children. Primary natural infection and protective efficacy of live-vaccine-induced or naturally acquired immunity. N Engl J Med (1977) 1.32
Evaluation of a live, attenuated respiratory syncytial virus vaccine in infants. J Pediatr (1976) 1.31
Assessment of secondary attack rate and effectiveness of antiviral prophylaxis among household contacts in an influenza A(H1N1)v outbreak in Kobe, Japan, May-June 2009. Euro Surveill (2009) 1.30
Growth of influenza A virus in primary, differentiated epithelial cells derived from adenoids. J Virol (1996) 1.29
Production and secretion of high levels of recombinant human acetylcholinesterase in cultured cell lines: microheterogeneity of the catalytic subunit. Gene (1992) 1.28
Trials of influenza A/New Jersey/76 virus vaccine in normal children: an overview of age-related antigenicity and reactogenicity. J Infect Dis (1977) 1.26
Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network. J Infect Dis (1992) 1.25
One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther (2012) 1.24
Use of antiserum-coated latex particles for serotyping Streptococcus pneumoniae. Microbiol Immunol (2001) 1.23
Vimentin is a novel AKT1 target mediating motility and invasion. Oncogene (2010) 1.23
Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients. Clin Pharmacol Ther (2008) 1.23
Serum immunoglobulin G antibody subclass responses to respiratory syncytial virus F and G glycoproteins after primary infection. J Clin Microbiol (1986) 1.22
The clinical role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J (2007) 1.21
Respiratory syncytial virus infection in anti-mu-treated mice. J Virol (1991) 1.20
Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. J Infect Dis (1996) 1.19
Clinical features of cases of influenza A (H1N1)v in Osaka prefecture, Japan, May 2009. Euro Surveill (2009) 1.18
Experimental surveillance using data on sales of over-the-counter medications--Japan, November 2003-April 2004. MMWR Morb Mortal Wkly Rep (2005) 1.16
Electron microscopic studies of respiratory syncytial temperature-sensitive mutants. Arch Gesamte Virusforsch (1973) 1.16
Clinical studies of pneumococcal vaccines in infants. I. Reactogenicity and immunogenicity of two polyvalent polysaccharide vaccines. Rev Infect Dis (1981) 1.15
Secretory immunological response after intranasal inactivated influenza A virus vaccinations: evidence for immunoglobulin A memory. Infect Immun (1983) 1.14
Acetylcholinesterase peripheral anionic site degeneracy conferred by amino acid arrays sharing a common core. J Biol Chem (1994) 1.14
Age-related response to two Haemophilus influenzae type b vaccines. J Pediatr (1982) 1.14
Immune correlates of protection against influenza in the human challenge model. Dev Biol (Basel) (2003) 1.13
Role of respiratory tract proteases in infectivity of influenza A virus. J Infect Dis (1987) 1.13
Evaluation of the safety of amantadine-HC1 and the role of respiratory viral infections in children with cystic fibrosis. J Infect Dis (1976) 1.12
Evaluation of a temperature-sensitive mutant of respiratory syncytial virus in adults. J Infect Dis (1971) 1.12
A colorimetric microtiter plate PCR system detects respiratory syncytial virus in nasal aspirates and discriminates subtypes A and B. Diagn Microbiol Infect Dis (1999) 1.11
The effect of elimination of intersubunit disulfide bonds on the activity, assembly, and secretion of recombinant human acetylcholinesterase. Expression of acetylcholinesterase Cys-580----Ala mutant. J Biol Chem (1991) 1.10
A comparison of five serological tests for bovine brucellosis. Can J Vet Res (1986) 1.10
Comparative analysis of host responses related to immunosuppression between measles patients and vaccine recipients with live attenuated measles vaccines. Arch Virol (2001) 1.08
Household transmission of pandemic 2009 influenza A (H1N1) virus in Osaka, Japan in May 2009. J Infect (2010) 1.08
A new quadruple therapy for the eradication of Helicobacter pylori. Effect of pretreatment with omeprazole on the cure rate. J Gastroenterol (1998) 1.07
Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. Vaccine (2000) 1.07
Analysis of Japanese encephalitis epidemic in Western Nepal in 1997. Epidemiol Infect (2001) 1.06
Genetic characterisation of adenovirus type 8 isolated in Hiroshima city over a 15 year period. J Clin Pathol (2003) 1.06
Robot system for preparing lymphocyte chromosome. J Radiat Res (1992) 1.06
A new quadruple therapy for Helicobacter pylori: influence of resistant strains on treatment outcome. Aliment Pharmacol Ther (1999) 1.05
Aprotinin and similar protease inhibitors as drugs against influenza. Antiviral Res (2011) 1.05
Application of a timing protocol to the reduction of inter-plate variability in the indirect enzyme immunoassay for detection of anti-Brucella antibody. J Immunoassay (1985) 1.04
Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants. Vaccine (1999) 1.04
Lack of comparability between commonly used serological assays of immune response to Haemophilus influenzae vaccine. J Infect Dis (1987) 1.04
Association of Helicobacter pylori infection with atrophic gastritis and intestinal metaplasia. J Gastroenterol Hepatol (2000) 1.03